Replies to post #38781 on Curative Biotechnology Inc (CUBT)

[Wrangler1]

Totally agree. The story here is all about market cap based on their pipeline. As it stands now it is less than $18M. If the animal studies of the Metformin eye drop prove effective, then moves to human trials following the IND, then the question to Conix point is what is the value of the Metformin eye drop. Hard to predict but significantly higher than an $18M cap is a given. It is all about the current solutions in the market (injections). Who on earth would not trade an injection into the eye for an eye drop? Everyone! The market potential for a prescription eye drop to treat eye disease is massive.

[Eagle1]

CUBT: Metformin eye drops instead of a needle+Big Pharma+$B MC.

conix

Friday, July 01, 2022 8:34:34 AM

Re: iRobot post# 38778

Post#
38781
of 38786
The question is not what the price per share would be if Metformin eye drop formulation was proven effective and eventually sold to a Big Pharma. A number of steps will happen before that -- like an announced partnership with investment into the company--that will have an effect on the market capitalization of the company.

An effective therapy for AMD through direct delivery to the eye with no need of injections into the eye would be worth well over $2 Billion, imo. Depending upon how many shares there are outstanding at the time--regardless of a RS or not--it would be substantially higher than the current market cap even accounting for a capital raise.

In a perfect world, the company would be flush with cash and already on NASDAQ. Judging by the filings and charts, three years ago, this ticker symbol was worth basically nothing with no business plan or future.

jmo